The WATER IV AS trial aims to assess Aquablation as earlier intervention for men on active surveillance Procept BioRobotics has received a second FDA investigational device exemption (IDE) to allow ...

Both robot-assisted simple prostatectomy (RASP) and laser enucleation of the prostate (LEP) are safe and effective surgical options for large-volume benign prostatic hyperplasia (BPH), according to a ...

Abhinav Sidana, MD, a urologic oncologist at the University of Chicago Medicine (UChicago Medicine), has performed the first ...

It's not an easy conversation for men to have, but talking about prostate problems is important. Common symptoms include urinary frequency or urgency or difficulty going to the bathroom. For years, ...

PANAMA CITY, Fla. (WJHG/WECP) -May is American Stroke Month, which aims to raise awareness about strokes and their causes. There are several risk factors for stroke, and one of those is having AFib, ...

MINNEAPOLIS and ATLANTA, April 16, 2026 /PRNewswire/ -- Francis Medical, Inc., a privately held medical device company, today announced the continued expansion of its U.S. commercial launch with the ...

Virtual replicas of individual patients’ hearts have allowed doctors to refine and personalize a lifesaving medical procedure for dangerous rhythm disturbances. Heart models may be just the leading ...

Working with "digital twins" of patients' hearts, doctors improved cardiac ablation outcomes for patients with life-threatening arrythmias. In the first clinical trials for cardiac digital twins ...

Aquablation and Rezūm are established minimally invasive surgical therapies for benign prostatic hyperplasia (BPH) in men with moderate-sized prostates. However, direct real-world data comparing ...

TORONTO, March 27, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets AI-powered, ...

MINNEAPOLIS, March 25, 2026 /PRNewswire/ -- Francis Medical, Inc., a privately held medical device company, announced today the successful completion of the first commercial (non-clinical study) ...